vs

Side-by-side financial comparison of GREENPOWER MOTOR Co INC. (GP) and OCULAR THERAPEUTIX, INC (OCUL). Click either name above to swap in a different company.

OCULAR THERAPEUTIX, INC is the larger business by last-quarter revenue ($13.3M vs $7.2M, roughly 1.8× GREENPOWER MOTOR Co INC.). GREENPOWER MOTOR Co INC. runs the higher net margin — -65.6% vs -488.0%, a 422.3% gap on every dollar of revenue. On growth, GREENPOWER MOTOR Co INC. posted the faster year-over-year revenue change (-11.5% vs -22.4%).

GreenPower Motor Company Inc. is a Canadian electric bus manufacturer and distributor in North America. The company fabricates multiple zero-emission models, including transit buses, school buses, and double decker buses. GreenPower headquarters are in Vancouver, British Columbia, with a sales office in Rancho Cucamonga, California; an assembly facility in Porterville, California; and a production facility in South Charleston, West Virginia. Its stock is traded on Nasdaq the United States.

Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.

GP vs OCUL — Head-to-Head

Bigger by revenue
OCUL
OCUL
1.8× larger
OCUL
$13.3M
$7.2M
GP
Growing faster (revenue YoY)
GP
GP
+10.9% gap
GP
-11.5%
-22.4%
OCUL
Higher net margin
GP
GP
422.3% more per $
GP
-65.6%
-488.0%
OCUL

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
GP
GP
OCUL
OCUL
Revenue
$7.2M
$13.3M
Net Profit
$-4.7M
$-64.7M
Gross Margin
14.6%
88.0%
Operating Margin
-526.5%
Net Margin
-65.6%
-488.0%
Revenue YoY
-11.5%
-22.4%
Net Profit YoY
-2.1%
-33.6%
EPS (diluted)
$-0.17
$-0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GP
GP
OCUL
OCUL
Q4 25
$13.3M
Q3 25
$14.5M
Q2 25
$13.5M
Q1 25
$10.7M
Q4 24
$7.2M
$17.1M
Q3 24
$5.3M
$15.4M
Q2 24
$3.0M
$16.4M
Q1 24
$14.8M
Net Profit
GP
GP
OCUL
OCUL
Q4 25
$-64.7M
Q3 25
$-69.4M
Q2 25
$-67.8M
Q1 25
$-64.1M
Q4 24
$-4.7M
$-48.4M
Q3 24
$-4.7M
$-36.5M
Q2 24
$-5.4M
$-43.8M
Q1 24
$-64.8M
Gross Margin
GP
GP
OCUL
OCUL
Q4 25
88.0%
Q3 25
87.8%
Q2 25
85.6%
Q1 25
88.2%
Q4 24
14.6%
92.8%
Q3 24
8.6%
89.9%
Q2 24
7.4%
90.8%
Q1 24
91.0%
Operating Margin
GP
GP
OCUL
OCUL
Q4 25
-526.5%
Q3 25
-472.3%
Q2 25
-502.6%
Q1 25
-597.5%
Q4 24
-296.1%
Q3 24
-298.2%
Q2 24
-265.1%
Q1 24
-214.0%
Net Margin
GP
GP
OCUL
OCUL
Q4 25
-488.0%
Q3 25
-477.3%
Q2 25
-503.9%
Q1 25
-598.7%
Q4 24
-65.6%
-283.3%
Q3 24
-87.9%
-236.6%
Q2 24
-179.8%
-266.3%
Q1 24
-438.9%
EPS (diluted)
GP
GP
OCUL
OCUL
Q4 25
$-0.27
Q3 25
$-0.38
Q2 25
$-0.39
Q1 25
$-0.38
Q4 24
$-0.17
$-0.25
Q3 24
$-0.18
$-0.22
Q2 24
$-0.21
$-0.26
Q1 24
$-0.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GP
GP
OCUL
OCUL
Cash + ST InvestmentsLiquidity on hand
$621.1K
$737.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.1M
$654.3M
Total Assets
$37.4M
$808.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GP
GP
OCUL
OCUL
Q4 25
$737.1M
Q3 25
$344.8M
Q2 25
$391.1M
Q1 25
$349.7M
Q4 24
$621.1K
$392.1M
Q3 24
$116.9K
$427.2M
Q2 24
$528.3K
$459.7M
Q1 24
$482.9M
Stockholders' Equity
GP
GP
OCUL
OCUL
Q4 25
$654.3M
Q3 25
$258.2M
Q2 25
$305.9M
Q1 25
$265.9M
Q4 24
$2.1M
$315.3M
Q3 24
$4.2M
$352.0M
Q2 24
$8.6M
$377.7M
Q1 24
$408.0M
Total Assets
GP
GP
OCUL
OCUL
Q4 25
$808.1M
Q3 25
$410.9M
Q2 25
$451.3M
Q1 25
$405.9M
Q4 24
$37.4M
$457.9M
Q3 24
$39.4M
$490.4M
Q2 24
$43.5M
$517.1M
Q1 24
$538.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GP
GP
OCUL
OCUL
Operating Cash FlowLast quarter
$-1.1M
$-54.2M
Free Cash FlowOCF − Capex
$-57.1M
FCF MarginFCF / Revenue
-430.9%
Capex IntensityCapex / Revenue
21.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-216.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GP
GP
OCUL
OCUL
Q4 25
$-54.2M
Q3 25
$-50.7M
Q2 25
$-55.2M
Q1 25
$-44.7M
Q4 24
$-1.1M
$-39.4M
Q3 24
$-1.3M
$-36.6M
Q2 24
$-3.2M
$-24.8M
Q1 24
$-33.9M
Free Cash Flow
GP
GP
OCUL
OCUL
Q4 25
$-57.1M
Q3 25
$-56.7M
Q2 25
$-56.5M
Q1 25
$-46.6M
Q4 24
$-39.6M
Q3 24
$-36.6M
Q2 24
$-25.5M
Q1 24
$-34.1M
FCF Margin
GP
GP
OCUL
OCUL
Q4 25
-430.9%
Q3 25
-390.0%
Q2 25
-419.7%
Q1 25
-435.6%
Q4 24
-232.0%
Q3 24
-237.6%
Q2 24
-155.4%
Q1 24
-231.1%
Capex Intensity
GP
GP
OCUL
OCUL
Q4 25
21.4%
Q3 25
41.2%
Q2 25
9.3%
Q1 25
18.1%
Q4 24
1.2%
Q3 24
0.6%
Q2 24
4.5%
Q1 24
1.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons